Intravascular Catheters Market: as BD's USD 4.20 Billion acquisition of Edwards Lifesciences' Critical Care product group announced June 3, 2024 and closed September 3, 2024 integrates the gold-standard Swan Ganz pulmonary artery catheter and AI-enabled hemodynamic monitoring used in over 10,000 hospitals globally into BD Medical's Advanced Patient Monitoring segment to create the most comprehensive integrated vascular access and patient monitoring portfolio in the medical technology industry, the NHS Supply Chain's 2025 mandatory passive-safety activation requirement across all PIVC tenders converts conventional non-safety catheter procurement into a mandatory safety platform upgrade cycle generating 40 to 60 percent per-unit revenue uplift, so BD's MDS Vascular Access Management strong growth in FY2024 and FY2025 confirms platform-level market share concentration, and B. Braun's October 2024 completion of its five-year USD 1.00 Billion capacity programme adding 30 million IV sets annually confirms the global demand growth trajectory for IV therapy consumables at institutional procurement scale.

The global intravascular catheters market size was USD 14.82 Billion in 2025 and is expected to register a revenue CAGR of 6.4% during the forecast period. Market revenue growth is driven by factors such as BD's September 2024 acquisition of Edwards Lifesciences' Critical Care product group for USD 4.20 Billion creating the most comprehensive integrated vascular access and hemodynamic monitoring portfolio in the industry, the NHS Supply Chain's 2025 mandatory passive safety activation requirement converting conventional catheter procurement toward premium safety platforms at 40 to 60 percent per-unit price premiums, and B. Braun's October 2024 completion of a five-year USD 1.00 Billion capacity investment programme adding 30 million IV sets annually confirming the structural IV therapy demand growth trajectory. The first driving factor is BD's acquisition of Edwards Lifesciences' Critical Care product group, which invented the hemodynamic monitoring category per BD's acquisition announcement, encompassing the gold-standard Swan Ganz pulmonary artery catheter used in more than 10,000 hospitals globally, minimally invasive arterial pressure sensors, the FloTrac system, noninvasive cuffs, tissue oximetry sensors, and AI-enabled clinical decision support. The Critical Care product group generated USD 900 Million in revenue in 2023, with BD's FY2025 earnings confirming strong APM performance in BD Medical's first full year post-acquisition. The second driving factor is NHS 2025 mandatory passive safety PIVC activation removing conventional catheters from NHS procurement across England's 220 NHS acute hospital trusts. The third driving factor is BD's MDS Vascular Access Management strong growth in FY2024 and FY2025 confirming platform-level market share concentration. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way BD's integration of Edwards Critical Care into the Advanced Patient Monitoring segment creates a razors-and-blades commercial model where the Swan Ganz PA catheter gets the patient into the BD monitoring ecosystem and the AI analytics platform generates recurring subscription revenue independent of physical catheter volume, converting what was previously a pure consumable volume business into a compounding platform revenue model that sustains BD's intravascular catheter revenue above the underlying procedure volume growth rate. Once a hospital's supply chain director negotiates a comprehensive vascular access and monitoring contract with BD covering PIVC, PICC, CVC, arterial catheter, PA catheter, and hemodynamic monitoring analytics from a single supplier, each new ICU patient admitted to that hospital generates revenue across multiple BD catheter and monitoring product categories simultaneously, compounding BD's per-hospital revenue above what individual product-category procurement relationships would generate. As a result, demand and revenue share are concentrating around BD whose combined MDS catheter portfolio and APM hemodynamic monitoring platform creates a comprehensive single-supplier contracting value proposition that Teleflex, B. Braun, and ICU Medical cannot replicate without equivalent hemodynamic monitoring capability. For instance, in November 2023, BD introduced the PIVO Pro needle-free blood draw system designed for use with peripheral IV catheters to reduce multiple needle sticks, enabling blood collection from existing peripheral IV catheter lumens without additional venipuncture, representing an accessory innovation that improves patient experience and reduces staff time for routine blood sampling alongside the primary catheter revenue stream. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is BD's creation through the September 2024 Edwards Critical Care acquisition of the only medical technology company that simultaneously supplies the peripheral IV catheter, central venous catheter, arterial catheter, pulmonary artery catheter, and hemodynamic monitoring analytics for the critically ill patient from a single corporate relationship, creating single-supplier contracting value that allows BD to command comprehensive vascular access contract positions at hospital systems that previously sourced catheter categories from multiple vendors. Single-supplier integration works as a compounding demand driver because hospital supply chain directors who consolidate vascular access and hemodynamic monitoring procurement into a single BD contract extract volume commitment discounts from BD while BD extracts comprehensive category exclusivity that locks out competing catheter suppliers across all categories simultaneously, so the per-hospital annual BD catheter and monitoring revenue is structurally higher under consolidated contracting than under competitive individual-category procurement. BD announced on June 3, 2024 a definitive agreement to acquire Edwards Lifesciences' Critical Care product group for USD 4.20 Billion in cash per BD's SEC Form 8-K, with Edwards Critical Care being described as the inventor of the hemodynamic monitoring category with solutions including the gold-standard Swan Ganz pulmonary artery catheter in more than 10,000 hospitals globally and AI-based predictive algorithms providing clinical decision support for haemodynamically unstable patients. The Critical Care product group generated USD 900 Million in revenue in 2023, and BD's FY2025 full-year earnings confirmed strong APM performance within BD Medical. BD's Medication Delivery Solutions unit reported strong Vascular Access Management growth in both FY2024 and FY2025, with the growth partially offset by volume-based procurement dynamics in China per BD earnings. The effect on the market is a structural consolidation of the premium intravascular catheter and hemodynamic monitoring category around BD's integrated platform. These are some of the key factors driving revenue growth of the market.

The second driver is the regulatory convergence of NHS 2025 mandatory passive safety activation in the UK and OSHA bloodborne pathogen enforcement in the US creating coordinated regulatory pressure for safety PIVC platform adoption across the two largest high-per-unit-ASP IV catheter markets simultaneously, generating a market-wide technology upgrade cycle from conventional to safety-engineered peripheral IV catheters that commands per-unit pricing 40 to 60 percent above commodity catheter pricing. Coordinated regulatory safety mandates work as compounding demand drivers because they convert the per-unit price premium from a voluntary upgrade argument into a regulatory compliance requirement that hospital procurement committees cannot refuse on cost grounds alone without exposing the hospital to regulatory enforcement risk, so the total addressable market for premium safety PIVC platforms expands at every hospital that previously declined safety platform upgrades on cost grounds. The NHS Supply Chain's 2025 Medical Devices Framework for vascular access established passive safety activation as a mandatory criterion in all PIVC category tenders, effectively excluding conventional non-safety catheters from NHS procurement across England's 220 NHS acute hospital trusts and creating a market-wide supply transition from conventional to safety-engineered peripheral IV catheters. OSHA's Bloodborne Pathogen Standard enforcement in the United States requires healthcare employers to use safety-engineered sharps devices including safety PIVCs with passive or automatic needle retraction when commercially available, providing a regulatory compliance driver sustaining premium safety PIVC demand at US hospitals. B. Braun raised IV fluid output by 20% and added 30 million IV sets annually after a five-year USD 1.00 Billion capacity investment programme per October 2024 published reports, confirming global IV therapy supply chain expansion alongside the safety PIVC upgrade cycle. The effect on the market is a structural per-unit revenue mix shift from low-cost conventional catheters to premium safety platforms that compounds as the NHS and OSHA regulatory frameworks are replicated in other national healthcare procurement systems. These are some of the key factors driving revenue growth of the market.

"The BD acquisition of Edwards' Critical Care business for USD 4.20 billion is the most strategically significant transaction in the intravascular catheter market in the past decade because it unifies the world's largest peripheral and central venous catheter manufacturer with the inventor of hemodynamic monitoring. Before this acquisition, BD supplied the PIVC, CVC, and arterial line while Edwards supplied the PA catheter and hemodynamic monitor. Now BD supplies all four plus the monitoring system, and a hospital supply chain director can negotiate a comprehensive vascular access and monitoring contract with a single supplier. That is a fundamentally different commercial relationship."

Clarivant Analyst Intelligence, Q1 2026

The third driver is material innovation beyond conventional polyurethane through hydrophilic biomaterial, silicone, and fluoropolymer catheter platforms that reduce phlebitis incidence and extend catheter dwell time in outpatient and home infusion settings, creating per-patient catheter consumption reduction that simultaneously improves patient experience and reduces the number of catheter insertion procedures required per infusion course. Material innovation works as a structural demand driver because catheter material improvements that demonstrably reduce phlebitis incidence justify premium unit pricing to hospital and home infusion procurement through evidence-based total cost of care arguments, where the reduced catheter replacement rate from fewer phlebitis-driven reinsertion procedures saves nursing time and supply cost per infusion course that offsets the higher per-unit premium catheter price. Access Vascular's hydrophilic biomaterial HF PIV catheter announced a partnership with Capstone Health Alliance in September 2024, expanding institutional access to its reduced-phlebitis catheter platform through the Capstone group purchasing organisation network. Silicone catheter material is expected to register the fastest CAGR within peripheral IV catheter materials, driven by silicone's lower modulus of elasticity reducing mechanical phlebitis incidence relative to polyurethane in applications with dwell times beyond 72 hours in outpatient and home infusion settings. BD's PIVC portfolio expansion of the Nexiva Closed IV Catheter System into Asian and Latin American hospital markets in 2025 confirms that integrated closed-system safety PIVC platforms are being adopted beyond the established North American and European safety PIVC markets. The effect on the market is a structural premium catheter material adoption cycle that simultaneously improves patient outcomes and justifies premium unit pricing above commodity polyurethane catheters across outpatient, infusion clinic, and home infusion channels. These are some of the key factors driving revenue growth of the market.

However, the intravascular catheters market faces adoption constraints from the clinical imperative to reduce catheter utilisation through daily removal assessment and evidence-based catheter selection, from China volume-based procurement compressing per-unit ASP in the world's largest procedural volume catheter market, and from GPO pricing leverage limiting per-unit ASP growth in the commodity PIVC segment. The catheter utilisation reduction imperative is the most significant structural headwind, since CDC Healthcare-Associated Infections data documenting over 25,000 US CRBSI events annually and CMS hospital-acquired condition penalties incentivising catheter utilisation reduction programmes create quality improvement pressure to remove catheters at the earliest clinically appropriate time, reducing per-patient catheter volume even as hospital census grows and partially offsetting the per-unit revenue growth from safety platform mix shift. China VBP dynamics are a second constraint confirmed by BD's FY2024 and FY2025 quarterly earnings, which consistently noted that Vascular Access Management growth was partially offset by volume-based procurement pricing compression in China that limits the revenue contribution from the world's largest absolute procedural volume catheter market. GPO negotiation leverage is a third constraint, since BD, B. Braun, Smiths Medical, Terumo, and Teleflex compete for group purchasing organisation peripheral IV catheter contracts at per-unit prices that are constrained by GPO negotiation leverage and commodity catheter substitution risk, preventing any single manufacturer from raising per-unit ASP above the GPO contracted rate by switching hospitals to safety or premium catheter platforms that have not been included in the GPO formulary for the contract period. These factors substantially limit intravascular catheters market growth over the forecast period.

Based on product type, the global intravascular catheters market is segmented into peripheral IV catheters, central venous catheters, pulmonary artery catheters, arterial catheters, and specialty vascular access devices. Peripheral IV catheters hold the largest revenue share at approximately 42% of 2025 market revenue as the highest-volume catheter segment, with the short PIVC subcategory generating approximately 66% of PIVC revenue in 2024 per published analyses. The integrated and closed PIVC subcategory is experiencing the fastest volume growth driven by NHS 2025 mandatory passive safety activation, OSHA enforcement, and EU Needlestick Directive compliance. Central venous catheters account for approximately 28% of 2025 market revenue encompassing non-tunnelled CVCs for ICU access, PICCs for oncology and IV antibiotic patients, and tunnelled CVCs for long-term dialysis access. Pulmonary artery catheters including the Edwards Lifesciences Swan Ganz catheter through BD APM represent approximately 14% of market revenue at the highest per-unit average selling price within the intravascular catheter market.

Based on technology, the global intravascular catheter market is segmented into conventional PIVCs, safety PIVCs, and integrated closed-system PIVCs. Integrated and closed-system PIVCs represent the fastest-growing technology subcategory within the peripheral IV catheter market, driven by NHS UK mandatory passive safety requirement in 2025 PIVC tenders, OSHA bloodborne pathogen enforcement in the US, and EU Needlestick Directive compliance requirements across European hospital markets. BD's Nexiva Closed IV Catheter System, which integrates catheter, blood control septum, and extension set in a closed architecture eliminating open-system blood exposure risks, represents the market's leading closed PIVC platform. Silicone catheter materials are expected to register the fastest CAGR within peripheral IV catheter materials, driven by silicone's lower modulus reducing phlebitis incidence compared to polyurethane in longer dwell-time outpatient and home infusion applications.

Based on regional analysis, the intravascular catheters market in North America accounted for the largest revenue share in 2025 at approximately 38% of global revenue. The United States drives the regional position through OSHA bloodborne pathogen enforcement requiring safety-engineered PIVC adoption at all US hospitals, CMS hospital-acquired condition penalties for CRBSI events incentivising infection prevention catheter technology investment, and the highest per-unit catheter average selling price globally reflecting the premium safety PIVC and closed-system technology mix adopted by US hospitals. BD holds approximately 30 to 35% of the US peripheral IV catheter market through its MDS Vascular Access Management portfolio, and the BD-Edwards Critical Care integration creating the APM Advanced Patient Monitoring business, with USD 900 Million Edwards Critical Care 2023 revenues plus the existing BD hemodynamic catheter portfolio, establishes BD as the US market leader in combined peripheral and central vascular access plus hemodynamic monitoring.

The market in Europe is expected to register a rapid revenue growth rate over the forecast period. Germany, France, the United Kingdom, Italy, and Spain represent the five largest national intravascular catheter markets within Europe. The NHS Supply Chain's 2025 mandatory passive safety activation requirement across all PIVC tenders represents a structural regulatory driver for safety PIVC adoption in the UK's NHS procurement system, requiring NHS hospital trusts to transition their PIVC supply contracts to safety-compliant platforms. Germany's hospital infection prevention regulations under the Robert Koch Institute guidelines require documented infection control measures for all central venous catheter insertions. Iran-US sanctions and Strait of Hormuz disruption through 2026 affect specialty polymer and catheter component supply chains for European catheter manufacturers, adding import cost pressure to European hospital catheter supply chains.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, Japan, India, Australia, and South Korea represent the five largest national intravascular catheter markets within the region. China's hospital expansion and growing inpatient volume generate the largest absolute PIVC and CVC procedure volumes in Asia Pacific, though BD's FY2024 and FY2025 earnings repeatedly noted China's volume-based procurement dynamics creating headwinds for MDS Vascular Access Management revenue. Japan's hospital infection prevention standards support safety PIVC adoption, with BD Japan, Terumo, and Nipro distributing peripheral IV and central venous catheter products across Japanese hospital purchasing frameworks.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil, Mexico, Colombia, Argentina, and Chile represent the primary national intravascular catheter markets within the region. BD Brazil distributes peripheral IV catheters, PICCs, and central venous catheters through established Brazilian hospital distribution networks serving both SUS public hospital facilities and private healthcare groups. BD is expanding commercial distribution of the Nexiva Closed IV Catheter System into Latin American hospital markets in 2025, confirming the emerging markets expansion of safety PIVC platform adoption.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia, the UAE, Turkey, Egypt, and South Africa represent the primary intravascular catheter markets within the region. Saudi Arabia's Ministry of Health hospital procurement network is one of the largest institutional buyers of peripheral IV catheters and central venous catheters in the Middle East, with BD, B. Braun, and Teleflex distributing vascular access products through registered Saudi medical device distributors. GCC Vision 2030 healthcare capacity expansion is driving new hospital construction that creates immediate catheter procurement needs at newly commissioned facilities.